Kymera Therapeutics (KYMR) News Today

$20.77

+0.01 (+0.05%)

(As of 12/1/2023 ET)

Today's Range: $19.73
▼
$20.97
50-Day Range: $10.97
▼
$20.89
52-Week Range: $9.60
▼
$39.85

Volume: 364,797 shs
Average Volume: 736,775 shs
Market Capitalization: $1.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.30

Source

Source	Headline
	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts americanbankingnews.com - November 25 at 3:32 AM
	Analyst Expectations for Kymera Therapeutics's Future markets.businessinsider.com - November 13 at 2:38 PM
	Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine finance.yahoo.com - November 13 at 2:38 PM
	Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases seekingalpha.com - November 12 at 2:27 AM
	BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc finance.yahoo.com - November 7 at 1:25 PM
	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 5 at 5:53 PM
	Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results es-us.finanzas.yahoo.com - November 4 at 10:13 PM
	HC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To Know markets.businessinsider.com - November 3 at 3:57 PM
	Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC) and Kymera Therapeutics (KYMR) markets.businessinsider.com - November 3 at 9:48 AM
	Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update finance.yahoo.com - November 2 at 8:35 AM
	Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update finance.yahoo.com - November 2 at 8:35 AM
	Preview: Kymera Therapeutics's Earnings benzinga.com - November 1 at 2:47 PM
	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi finance.yahoo.com - October 27 at 7:45 AM
	Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know finance.yahoo.com - October 26 at 3:19 PM
	Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2 finance.yahoo.com - October 26 at 10:18 AM
	Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner finance.yahoo.com - October 19 at 3:21 PM
	Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner finance.yahoo.com - October 18 at 1:25 PM
	Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma finance.yahoo.com - October 16 at 8:18 AM
	Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock? finance.yahoo.com - October 4 at 8:46 AM
	Why Shares of Kymera Therapeutics Jumped on Tuesday finance.yahoo.com - October 3 at 8:44 PM
	Harbor Capital Advisors Inc. Buys 20,059 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) marketbeat.com - September 19 at 6:38 AM
	Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma finance.yahoo.com - September 18 at 9:22 AM
	Kymera Therapeutics, Inc. (NASDAQ:KYMR) is Atlas Venture Life Science Advisors LLC's Largest Position marketbeat.com - September 12 at 6:13 AM
	Profund Advisors LLC Makes New $1.15 Million Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) marketbeat.com - September 1 at 7:53 AM
	Industry Analysts Just Upgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts By 19% finance.yahoo.com - August 31 at 7:29 AM
	Morgan Stanley Maintains Kymera Therapeutics (KYMR) Equal-Weight Recommendation msn.com - August 30 at 9:23 AM
	The Latest Analyst Ratings for Kymera Therapeutics markets.businessinsider.com - August 29 at 6:23 PM
	Kymera Therapeutics to Participate in Upcoming September Investor Conferences finance.yahoo.com - August 28 at 10:10 AM
	Kymera Therapeutics - Need More Developments Before Making This A Buy msn.com - August 9 at 5:40 PM
	SG Americas Securities LLC Invests $260,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR) marketbeat.com - August 9 at 4:35 AM
	Stifel Maintains Kymera Therapeutics (KYMR) Buy Recommendation msn.com - August 8 at 1:21 PM
	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Position Trimmed by Barclays PLC marketbeat.com - August 8 at 6:11 AM
	Truist Financial Sticks to Its Buy Rating for Kymera Therapeutics (KYMR) markets.businessinsider.com - August 7 at 2:55 AM
	Kymera Therapeutics: A Status Update seekingalpha.com - August 6 at 7:21 AM
	Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results marketbeat.com - August 4 at 8:24 PM
	H.C. Wainwright Sticks to Its Buy Rating for Kymera Therapeutics (KYMR) markets.businessinsider.com - August 4 at 5:50 PM
	HC Wainwright & Co. Reiterates Kymera Therapeutics (KYMR) Buy Recommendation msn.com - August 4 at 5:50 PM
	Expert Ratings for Kymera Therapeutics markets.businessinsider.com - August 4 at 5:50 PM
	Credit Suisse Group Boosts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $37.00 marketbeat.com - August 4 at 11:26 AM
	Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update finance.yahoo.com - August 3 at 8:37 AM
	Kymera Therapeutics (KYMR) Set to Announce Quarterly Earnings on Thursday marketbeat.com - July 28 at 10:17 AM
	Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3 finance.yahoo.com - July 27 at 10:56 AM
	Raymond James & Associates Has $679,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) marketbeat.com - July 25 at 4:20 AM
	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Moderate Buy" by Analysts marketbeat.com - July 23 at 4:36 AM
	Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth finance.yahoo.com - July 9 at 10:20 AM
	Truist Securities Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation msn.com - July 1 at 12:21 PM
	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Moderate Buy" from Analysts marketbeat.com - June 28 at 4:30 AM
	FDA grants orphan drug status to Kymera blood cancer drug KT-253 seekingalpha.com - June 22 at 2:16 PM
	Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia finance.yahoo.com - June 22 at 9:16 AM
	Board Member at Kymera Therapeutics Acquires Company Stock Options Worth 12,000 Shares benzinga.com - June 21 at 1:20 PM

Get Kymera Therapeutics News Delivered to You Automatically

KYMR Media Mentions By Week

KYMR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KYMR
News Sentiment
▼
1.23

0.76
▲
Average
Medical
News Sentiment

KYMR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KYMR Articles
This Week
▼
1

2
▲
KYMR Articles
Average Week

Get Kymera Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:KYMR) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kymera Therapeutics (KYMR) News Today

KYMR Media Mentions By Week

KYMR Media Sentiment

KYMR News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info